These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3066620)

  • 21. Investigation into the role of cephalic stimulation of acid secretion on gastric emptying and appetite following a soup meal using the gastric acid inhibitor omeprazole.
    Cecil JE; Francis J; Read NW
    Appetite; 2004 Feb; 42(1):99-105. PubMed ID: 15036788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acute tryptophan depletion slows gastric emptying in females.
    van Nieuwenhoven MA; Valks SD; Sobczak S; Riedel WJ; Brummer RJ
    Br J Nutr; 2004 Mar; 91(3):351-5. PubMed ID: 15005820
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of anti-obesity drugs promoting energy expenditure, yohimbine and ephedrine, on gastric emptying in obese patients.
    Jonderko K; Kucio C
    Aliment Pharmacol Ther; 1991 Aug; 5(4):413-8. PubMed ID: 1777550
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Obesity does not increase effects of synthetic ghrelin on human gastric motor functions.
    Cremonini F; Camilleri M; Vazquez Roque M; McKinzie S; Burton D; Baxter K; Zinsmeister AR
    Gastroenterology; 2006 Nov; 131(5):1431-9. PubMed ID: 17101319
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Gastric emptying studies in the morbidly obese before and after gastroplasty.
    Christian PE; Datz FL; Moore JG
    J Nucl Med; 1986 Nov; 27(11):1686-90. PubMed ID: 3772503
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of botulinum toxin antral injection on gastric emptying and weight reduction in obese patients: a pilot study.
    Gui D; Mingrone G; Valenza V; Spada PL; Mutignani M; Runfola M; Scarfone A; Di Mugno M; Panunzi S
    Aliment Pharmacol Ther; 2006 Mar; 23(5):675-80. PubMed ID: 16480407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)].
    Gołebiowska M; Chlebna-Sokół D; Kobierska I; Konopińska A; Małek M; Mastalska A; Zwaigzne-Raczyńska J
    Przegl Lek; 1981; 38(3):355-8. PubMed ID: 7017827
    [No Abstract]   [Full Text] [Related]  

  • 28. [Treatment of obesity with a non-amphetamine anorexigenic agent (author's transl)].
    Riesco J; Troncoso G; Costamaillere L; Rodríguez J
    Rev Med Chil; 1977 Jun; 105(6):375-9. PubMed ID: 331428
    [No Abstract]   [Full Text] [Related]  

  • 29. A double blind controlled trial of a new anorectic agent AN448.
    Woodhouse SP; Nye ER; Anderson K; Rawlings J
    N Z Med J; 1975 Jun; 81(542):546-9. PubMed ID: 1099491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alteration of gastric functions and candidate genes associated with weight reduction in response to sibutramine.
    Vazquez Roque MI; Camilleri M; Clark MM; Tepoel DA; Jensen MD; Graszer KM; Kalsy SA; Burton DD; Baxter KL; Zinsmeister AR
    Clin Gastroenterol Hepatol; 2007 Jul; 5(7):829-37. PubMed ID: 17544870
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibitory effect of cigarette smoking on gastric emptying of a solid meal in patients with type I gastric ulcer.
    Nowak A; Jonderko K; Kaczor R; Nowak S; Adamczak D; Rudzki K
    Z Gastroenterol; 1991 Feb; 29(2):45-8. PubMed ID: 1871998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Mazindol (Teronac) in the treatment of predominant by food-dependent obesity].
    Husmann F
    Med Welt; 1976 Oct; 27(40):1904-8. PubMed ID: 790077
    [No Abstract]   [Full Text] [Related]  

  • 33. Relationship between acceleration of gastric emptying and oesophageal acid exposure in patients with endoscopy-negative gastro-oesophageal reflux disease.
    Carmagnola S; Fraquelli M; Cantù P; Conte D; Penagini R
    Scand J Gastroenterol; 2006 Jul; 41(7):767-72. PubMed ID: 16785188
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A double-blind trial of mazindol using a very low calorie formula diet.
    Baird IM; Howard AN
    Int J Obes; 1977; 1(3):271-8. PubMed ID: 363631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of morbid obesity by intraparietogastric administration of botulinum toxin: a randomized, double-blind, controlled study.
    Foschi D; Corsi F; Lazzaroni M; Sangaletti O; Riva P; La Tartara G; Bevilacqua M; Osio M; Alciati A; Bianchi Porro G; Trabucchi E
    Int J Obes (Lond); 2007 Apr; 31(4):707-12. PubMed ID: 17006442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Anorexiant drugs in the ambulant treatment of obese patients (author's transl)].
    Jenny S; Zimmermann KG; Radielovic P; Bühlmann AA
    Schweiz Rundsch Med Prax; 1976 Jul; 65(28):874-8. PubMed ID: 1005298
    [No Abstract]   [Full Text] [Related]  

  • 37. Double-blind clinical evaluation of mazindol (42-548) in obese diabetics.
    Bandisode MS; Boshell BR
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):816-24. PubMed ID: 813947
    [No Abstract]   [Full Text] [Related]  

  • 38. Effects of nitric oxide on antral motility and gastric emptying in humans.
    Konturek JW; Thor P; Domschke W
    Eur J Gastroenterol Hepatol; 1995 Feb; 7(2):97-102. PubMed ID: 7712314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Comparative trial on the effects of diet, mazindol, and placebo in the treatment of exogenous obesity (author's transl)].
    Mies R
    Med Klin; 1976 Nov; 71(46):2013-6. PubMed ID: 995040
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A simple isotope method for studying of gastric emptying of solid foods].
    Dobó I; Szilvási I; Pastinszky I; Kun M
    Orv Hetil; 1989 May; 130(19):995-7. PubMed ID: 2542862
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.